● Recruiting

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Condition: Cholangiocarcinoma · Sponsor: Genfit

PhasePhase 1/Phase 2

Planned participants98

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is an open-label, multicenter Phase 1b/2a study to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of GNS561 in combination with trametinib in Advanced KRAS Mutated Cholangiocarcinoma after failure of standard-of-care first line therapy

This description comes directly from the study's public registry record.

Talk to the study team

Pejvack MOTLAGH, CMO · +33320164092 · contact@genfit.com

Pejvack MOTLAGH, CMO · +33320164092 · pejvack.motlagh@genfit.com

Always discuss trial participation with your own doctor first.

Locations (11)

USC Norris Comprehensive Cancer Center	Los Angeles, California, United States	Recruiting
LACN Aneheim Flagship Office	Los Angeles, California, United States	Recruiting
Orlando Health	Orlando, Florida, United States	Recruiting
Moffitt Cancer Center	Tampa, Florida, United States	Recruiting
University Of Chicago Medical Center	Chicago, Illinois, United States	Recruiting
Roswell Park Cancer Institute	Buffalo, New York, United States	Terminated
Hospital of the University of Pennsylvania	Philadelphia, Pennsylvania, United States	Terminated
University of Texas, MD Anderson Cancer Center	Houston, Texas, United States	Recruiting
University of Virginia Comprehensive Cancer Center	Charlottesville, Virginia, United States	Recruiting
Froedtert Hospital and the Medical College of Wisconsin	Milwaukee, Wisconsin, United States	Recruiting
Pan American Center for Oncology Trials, LLC	Rio Piedras, Puerto Rico, Puerto Rico	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05874414